Monthly 60,000 IU of Vitamin D did not reduce mortality (too infrequent)- Feb 2022monthly) will reduce mortality – results due 2024

Created April 2016

Poor results published Mortality reduction needs more than monthly 60,000 IU of Vitamin D - RCT Jan 2022

The D-Health Trial: A randomized trial of vitamin D for prevention of mortality and cancer

Contemporary Clinical Trials, Available online 14 April 2016, doi:10.1016/j.cct.2016.04.005

R.E. Nealea, , , B.K. Armstrongb, C. Baxtera, B. Duarte Romeroa, P. Ebelingc, D.R. Englishd, M.G. Kimline, D.S.A. McLeoda, R.L. O′Connellf, J.C. van der Polsg, A.J. Vennh, P.M. Webba, D.C. Whitemana, L. Wocknera

VitaminDWiki expects that little results will be found with 60,000 IU monthly Elderly need at least 50,000 IU weekly, not monthly, and, one size does NOT fill all Random Controlled trials rarely use dose sizes which vary by weight, pre-existing conditions, etc. See also VitaminDWikii * VITAMIN D: Public Shouldn’t Wait For Doctors To Usher In New “Golden Era” Of Preventive Medicine * Vitamin D home fortification- don't wait 100 years for your govt * Molecular Approaches for Optimizing Vitamin D (one size does not fit all) – Carlberg Nov 2015 13 reasons why many seniors need more vitamin D (both dose and level) - July 2023 has the following {include} The Meta-analysis of Mortality and Vitamin D are listed here: {category} The Meta-analysis of Mortality and Intervention are listed here: {category}

Promising Vitamin D Clinical Trials - 2017 contains the following

{include}

Background:

Vitamin D, specifically serum 25(OH)D has been associated with mortality, cancer and multiple other health endpoints in observational studies, but there is a paucity of clinical trial evidence sufficient to determine the safety and effectiveness of population-wide supplementation. We have therefore launched the D-Health Trial, a randomized trial of vitamin D supplementation for prevention of mortality and cancer. Here we report the methods and describe the trial cohort.

Methods:

The D-Health Trial is a randomized placebo-controlled trial, with planned intervention for 5 years and a further 5 years of passive follow-up through linkage with health and death registers. Participants aged 65–84 years were recruited from the general population of Australia. The intervention is monthly oral doses of 60,000 IU of cholecalciferol or matching placebo. The primary outcome is all-cause mortality. Secondary outcomes are total cancer incidence and colorectal cancer incidence.

Results: We recruited 21,315 participants to the trial between February 2014 and May 2015. The participants in the two arms of the trial were well-balanced at baseline. Comparison with Australian population statistics shows that the trial participants were less likely to report being in fair or poor health, to be current smokers or to have diabetes than the Australian population. However, the proportion overweight or with health conditions such as arthritis and angina was similar.

Conclusions:

Observational data cannot be considered sufficient to support interventions delivered at a population level. Large-scale randomized trials such as the D-Health Trial are needed to inform public health policy and practice.

Tags: Mortality